Skip to main content
SpringerLink
Log in

Cardiac Sarcoidosis

  • Chapter
  • First Online:
FDG-PET/CT and PET/MR in Cardiovascular Diseases

  • 329 Accesses

Abstract

FDG-PET has become a well-established imaging tool for the assessment of patients with suspected cardiac sarcoidosis. PET offers high diagnostic accuracy, in addition to providing important prognostic information, and may serve as an ideal test for the follow-up of response to therapy. In this chapter, we review the use of PET imaging in patients with cardiac sarcoidosis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Roberts WC, McAllister HA Jr, Ferrans VJ. Sarcoidosis of the heart: a clinicopathologic study of 35 necropsy patients (group I) and review of 78 previously described necropsy patients (group II). Am J Med. 1977;63(1):86–108.

    Article  CAS  PubMed  Google Scholar 

  2. Yazaki Y, Isobe M, Hiroe M, Morimoto S, Hiramitsu S, Nakano T, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 2001;88(9):1006–10.

    Article  CAS  PubMed  Google Scholar 

  3. Reuhl J, Schneider M, Sievert H, Lutz F-U, Zieger G. Myocardial sarcoidosis as a rare cause of sudden cardiac death. Forensic Sci Int. 1997;89(3):145–53.

    Article  CAS  PubMed  Google Scholar 

  4. Baughman R, Bresnitz E, Iannuzzi M, Johns C, Knatterud GL, McLennan G, et al. Design of a Case Control Etiologic Study of sarcoidosis (ACCESS). J Clin Epidemiol. 1999;52(12):1173–86.

    Article  Google Scholar 

  5. Rybicki BA, Iannuzzi MC, Frederick MM, Thompson BW, Rossman MD, Bresnitz EA, et al. Familial aggregation of sarcoidosis. Am J Respir Crit Care Med. 2001;164(11):2085–91.

    Article  CAS  PubMed  Google Scholar 

  6. Sverrild A, Backer V, Kyvik KO, Kaprio J, Milman N, Svendsen CB, et al. Heredity in sarcoidosis: a registry-based twin study. Thorax. 2008;63(10):894–6.

    Article  CAS  PubMed  Google Scholar 

  7. Baughman R, Lower EE, du Bois RM. Sarcoidosis. Lancet. 2003;361:1111–8.

    Article  CAS  PubMed  Google Scholar 

  8. Costabel U, Hunninghake GW. ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis statement committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders. Eur Respir J. 1999;14(4):735–7.

    Article  CAS  PubMed  Google Scholar 

  9. Grunewald J, Kaiser Y, Ostadkarampour M, Rivera NV, Vezzi F, Lötstedt B, et al. T-cell receptor–HLA-DRB1 associations suggest specific antigens in pulmonary sarcoidosis. Eur Respir J. 2016;47(3):898–909.

    Article  CAS  PubMed  Google Scholar 

  10. Rosen Y. Pathology of sarcoidosis. In: Respiratory and critical care medicine. New York: Thieme Medical; 2007. p. 036–52.

    Google Scholar 

  11. Mochizuki T, Tsukamoto E, Kuge Y, Kanegae K, Zhao S, Hikosaka K, et al. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med. 2001;42(10):1551–5.

    CAS  PubMed  Google Scholar 

  12. Maratou E, Dimitriadis G, Kollias A, Boutati E, Lambadiari V, Mitrou P, et al. Glucose transporter expression on the plasma membrane of resting and activated white blood cells. Eur J Clin Invest. 2007;37(4):282–90.

    Article  CAS  PubMed  Google Scholar 

  13. Arkema EV, Grunewald J, Kullberg S, Eklund A, Askling J. Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden. Eur Respir J. 2016;48(6):1690–9.

    Article  PubMed  Google Scholar 

  14. Baughman RP, Field S, Costabel U, Crystal RG, Culver DA, Drent M, et al. Sarcoidosis in America analysis based on health care use. ATS. 2016;13(8):1244–52.

    Article  Google Scholar 

  15. Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H Jr, Bresnitz EA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164(10):1885–9.

    Article  CAS  PubMed  Google Scholar 

  16. Mehta D, Lubitz SA, Frankel Z, Wisnivesky JP, Einstein AJ, Goldman M, et al. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest. 2008;133(6):1426–35.

    Article  PubMed  Google Scholar 

  17. Nagai T, Kohsaka S, Okuda S, Anzai T, Asano K, Fukuda K. Incidence and prognostic significance of myocardial late gadolinium enhancement in patients with sarcoidosis without cardiac manifestation. Chest. 2014;146(4):1064–72.

    Article  PubMed  Google Scholar 

  18. Patel MR, Cawley PJ, Heitner JF, Igor K, Parker MA, Jaroudi WA, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation. 2009;120(20):1969–77.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Pizarro C, Goebel A, Grohé C, Pabst S, Klein J, Nickenig G, et al. Cardiovascular magnetic resonance-guided diagnosis of cardiac affection in a Caucasian sarcoidosis population. Pneumologie. 2015;69(S1):P299.

    Google Scholar 

  20. Patel AR, Klein MR, Chandra S, Spencer KT, DeCara JM, Lang RM, et al. Myocardial damage in patients with sarcoidosis and preserved left ventricular systolic function: an observational study. Eur J Heart Fail. 2011;13(11):1231–7.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Greulich S, Deluigi CC, Gloekler S, Wahl A, ZĂ¼rn C, Kramer U, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2013;6(4):501–11.

    Article  PubMed  Google Scholar 

  22. Murtagh G, Laffin LJ, Beshai JF, Maffessanti F, Bonham CA, Patel AV, et al. Prognosis of myocardial damage in sarcoidosis patients with preserved left ventricular ejection fraction. Circ Cardiovasc Imaging. 2016;9(1):e003738. https://doi.org/10.1161/CIRCIMAGING.115.003738.

    Article  PubMed  PubMed Central  Google Scholar 

  23. DhĂ´te R, Vignaux O, Blanche P, Duboc D, Dusser D, Brezin A, et al. Apport de l’IRM dans l’exploration de l’atteinte cardiaque au cours de la sarcoĂ¯dose. Rev Med Interne. 2003;24(3):151–7.

    Article  PubMed  Google Scholar 

  24. Smedema J-P, Snoep G, van Kroonenburgh MPG, van Geuns R-J, Dassen WRM, Gorgels AP, et al. Cardiac involvement in patients with pulmonary sarcoidosis assessed at two university medical centers in the Netherlands. Chest. 2005;128(1):30–5.

    Article  PubMed  Google Scholar 

  25. Vignaux O, Dhote R, Duboc D, Blanche P, Devaux J-Y, Weber S, et al. Detection of myocardial involvement in patients with sarcoidosis applying T2-weighted, contrast-enhanced, and cine magnetic resonance imaging: initial results of a prospective study. J Comput Assist Tomogr. 2002;26(5):762–7.

    Article  PubMed  Google Scholar 

  26. Hulten E, Aslam S, Osborne M, Abbasi S, Bittencourt MS, Blankstein R. Cardiac sarcoidosis—state of the art review. Cardiovasc diagn ther. 2016;6(1):50.

    PubMed  PubMed Central  Google Scholar 

  27. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation. 1978;58(6):1204–11.

    Article  CAS  PubMed  Google Scholar 

  28. Iwai K, Tachibana T, Takemura T, Matsui Y, Kitalchi M, Kawabata Y. Pathological studies on sarcoidosis autopsy. I. Epidemiological features of 320 cases in Japan. Pathol Int. 1993;43(7–8):372–6.

    Article  CAS  Google Scholar 

  29. Perry A, Vuitch F. Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med. 1995;119(2):167–72.

    CAS  PubMed  Google Scholar 

  30. Hu X, Carmona EM, Yi ES, Pellikka PA, Ryu J. Causes of death in patients with chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2016;33(3):275–80.

    PubMed  Google Scholar 

  31. Chapelon-Abric C, de Zuttere D, Duhaut P, Veyssier P, Wechsler B, de Gennes C, et al. Cardiac sarcoidosis: a retrospective study of 41 cases. Medicine. 2004;83(6):315–34.

    Article  PubMed  Google Scholar 

  32. Matsui Y, Iwai K, Tachibana T, Fruie T, Shigematsu N, Izumi T, et al. Clinicopathological study on fatal myocardial sarcoidosis. Ann N Y Acad Sci. 1976;278(1):455–69.

    Article  CAS  PubMed  Google Scholar 

  33. Uusimaa P, Ylitalo K, Anttonen O, Kerola T, Virtanen V, Pääkkö E, et al. Ventricular tachyarrhythmia as a primary presentation of sarcoidosis. Europace. 2008;10(6):760–6.

    Article  PubMed  Google Scholar 

  34. Dubrey SW, Falk RH. Diagnosis and management of cardiac sarcoidosis. Prog Cardiovasc Dis. 2010;52(4):336–46.

    Article  PubMed  Google Scholar 

  35. Kandolin R, Lehtonen J, Kupari M. Cardiac sarcoidosis and giant cell myocarditis as causes of atrioventricular block in young and middle-aged adults. Circ Arrhythm Electrophysiol. 2011;4(3):303–9.

    Article  PubMed  Google Scholar 

  36. Nery PB, Beanlands RS, Nair GM, Green M, Yang J, McArdle BA, et al. Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-aged adults. J Cardiovasc Electrophysiol. 2014;25(8):875–81.

    Article  PubMed  Google Scholar 

  37. Nery PB, Mc Ardle BA, Redpath CJ, Leung E, Lemery R, Dekemp R, et al. Prevalence of cardiac sarcoidosis in patients presenting with monomorphic ventricular tachycardia. Pacing Clin Electrophysiol. 2014;37(3):364–74.

    Article  PubMed  Google Scholar 

  38. Tung R, Bauer B, Schelbert H, Lynch JP III, Auerbach M, Gupta P, et al. Incidence of abnormal positron emission tomography in patients with unexplained cardiomyopathy and ventricular arrhythmias: the potential role of occult inflammation in arrhythmogenesis. Heart Rhythm. 2015;12(12):2488–98.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Sekiguchi M, Numao Y, Imai M, Furuie T, Mikami R. Clinical and histopathological profile of sarcoidosis of the heart and acute idiopathic myocarditis concepts through a study employing endomyocardial biopsy I. sarcoidosis: symposium on secondary myocardial disease. Jpn Circ J. 1980;44(4):249–63.

    Article  CAS  PubMed  Google Scholar 

  40. Hiraga H. The guides for the diagnosis of cardiac sarcoidosis: report of the Japanese Research Committee for Diffuse Lung Disease of Japan Ministry Welfare; 1993. p. 23–4.

    Google Scholar 

  41. Hiraga H, Yuwai K, Hiroe M. Diagnostic standard and guidelines for sarcoidosis. Jpn J Sarcoidosis Granulomatous Disord. 2007;27:89–102.

    Google Scholar 

  42. Judson M, Baughman R, Teirstein A, Terrin M, Yeager H Jr. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS research group. A case control etiologic study of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16(1):75–86.

    CAS  PubMed  Google Scholar 

  43. Judson MA, Costabel U, Drent M, Wells A, Maier L, Koth L, et al. The WASOG sarcoidosis organ assessment instrument: an update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(1):19–27.

    PubMed  Google Scholar 

  44. Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11(7):1304–23.

    Article  Google Scholar 

  45. Neto MLR, Jellis C, Hachamovitch R, Wimer A, Highland KB, Sahoo D, et al. Performance of diagnostic criteria in patients clinically judged to have cardiac sarcoidosis: is it time to regroup? Am Heart J. 2020;223:106–9.

    Article  Google Scholar 

  46. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357(21):2153–65.

    Article  CAS  PubMed  Google Scholar 

  47. Ma J, Lee K-V, Stafford RS. Changes in antihypertensive prescribing during US outpatient visits for uncomplicated hypertension between 1993 and 2004. Hypertension. 2006;48(5):846–52.

    Article  CAS  PubMed  Google Scholar 

  48. d’Alessandro M, Bergantini L, Perrone A, Cameli P, Cameli M, Prasse A, et al. Serial investigation of angiotensin-converting enzyme in sarcoidosis patients treated with angiotensin-converting enzyme inhibitor. Eur J Intern Med. 2020;78:58–62.

    Article  PubMed  Google Scholar 

  49. Chopra A, Kalkanis A, Judson MA. Biomarkers in sarcoidosis. Expert Rev Clin Immunol. 2016;12(11):1191–208.

    Article  CAS  PubMed  Google Scholar 

  50. Uemura A, Morimoto S, Hiramitsu S, Kato Y, Ito T, Hishida H. Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies. Am Heart J. 1999;138(2):299–302.

    Article  CAS  PubMed  Google Scholar 

  51. Kandolin R, Lehtonen J, Graner M, Schildt J, Salmenkivi K, Kivistö S, et al. Diagnosing isolated cardiac sarcoidosis. J Intern Med. 2011;270(5):461–8.

    Article  CAS  PubMed  Google Scholar 

  52. Bennett MK, Gilotra NA, Harrington C, Rao S, Dunn JM, Freitag TB, et al. Evaluation of the role of endomyocardial biopsy in 851 patients with unexplained heart failure from 2000–2009. Circ Heart Fail. 2013;6(4):676–84.

    Article  PubMed  Google Scholar 

  53. Hutchinson J. Statement on sarcoidosis. Joint statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the world Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of directors and by the ER. Am J Respir Crit Care Med. 1999;160(736):55.

    Google Scholar 

  54. Okayama K, Kurata C, Tawarahara K, Wakabayashi Y, Chida K, Sato A. Diagnostic and prognostic value of myocardial scintigraphy with thallium-201 and gallium-67 in cardiac sarcoidosis. Chest. 1995;107(2):330–4.

    Article  CAS  PubMed  Google Scholar 

  55. Thunell M, Bjerle P, Stjernberg N. ECG abnormalities in patients with sarcoidosis. Acta Med Scand. 1983;213(2):115–8.

    Article  CAS  PubMed  Google Scholar 

  56. Fahy GJ, Marwick T, McCreery CJ, Quigley PJ, Maurer BJ. Doppler echocardiographic detection of left ventricular diastolic dysfunction in patients with pulmonary sarcoidosis. Chest. 1996;109(1):62–6.

    Article  CAS  PubMed  Google Scholar 

  57. Gibbons WJ, Levy RD, Nava S, Malcolm I, Marin JM, Tardif C, et al. Subclinical cardiac dysfunction in sarcoidosis. Chest. 1991;100(1):44–50.

    Article  CAS  PubMed  Google Scholar 

  58. Kim JS, Judson MA, Donnino R, Gold M, Cooper LT Jr, Prystowsky EN, et al. Cardiac sarcoidosis. Am Heart J. 2009;157(1):9–21.

    Article  CAS  PubMed  Google Scholar 

  59. Pizarro C, Goebel A, Dabir D, Hammerstingl C, Pabst S, Grohé C. Cardiovascular magnetic resonance-guided diagnosis of cardiac affection in a Caucasian sarcoidosis population. Sarcoidosis Vasc Diffuse Lung Dis. 2016;32(04):325–35.

    PubMed  Google Scholar 

  60. Ayyala US, Nair AP, Padilla ML. Cardiac sarcoidosis. Clin Chest Med. 2008;29(3):493–508.

    Article  PubMed  Google Scholar 

  61. Agarwal A, Sulemanjee NZ, Cheema O, Downey FX, Tajik AJ. Cardiac sarcoid: a chameleon masquerading as hypertrophic cardiomyopathy and dilated cardiomyopathy in the same patient. Echocardiography. 2014;31(5):E138–41.

    Article  PubMed  Google Scholar 

  62. Sköld C, Larsen F, Rasmussen E, Pehrsson S, Eklund A. Determination of cardiac involvement in sarcoidosis by magnetic resonance imaging and Doppler echocardiography. J Intern Med. 2002;252(5):465–71.

    Article  PubMed  Google Scholar 

  63. Burstow DJ, Tajik AJ, Bailey KR, De Remee RA, Taliercio CP. Two-dimensional echocardiographic findings in systemic sarcoidosis. Am J Cardiol. 1989;63(7):478–82.

    Article  CAS  PubMed  Google Scholar 

  64. Hourigan LA, Burstow DJ, Pohlner P, Clarke BE, Donnelly JE. Transesophageal echocardiographic abnormalities in a case of cardiac sarcoidosis. J Am Soc Echocardiogr. 2001;14(5):399–402.

    Article  CAS  PubMed  Google Scholar 

  65. Cummings KW, Bhalla S, Javidan-Nejad C, Bierhals AJ, Gutierrez FR, Woodard PK. A pattern-based approach to assessment of delayed enhancement in nonischemic cardiomyopathy at MR imaging. Radiographics. 2009;29(1):89–103.

    Article  PubMed  Google Scholar 

  66. Smedema J-P, Snoep G, van Kroonenburgh MP, van Geuns R-J, Dassen WR, Gorgels AP, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol. 2005;45(10):1683–90.

    Article  PubMed  Google Scholar 

  67. Slart RH, Glaudemans AW, Lancellotti P, Hyafil F, Blankstein R, Schwartz RG, et al. A joint procedural position statement on imaging in cardiac sarcoidosis: from the cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American society of nuclear cardiology. Eur Heart J Cardiovasc Imaging. 2017;18(10):1073–89.

    Article  Google Scholar 

  68. Chareonthaitawee P, Beanlands RS, Chen W, Dorbala S, Miller EJ, Murthy VL, et al. Joint SNMMI–ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring. J Nucl Med. 2017;58(8):1341–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Christopoulos G, Jouni H, Acharya GA, Blauwet LA, Kapa S, Bois J, et al. Suppressing physiologic 18-fluorodeoxyglucose uptake in patients undergoing positron emission tomography for cardiac sarcoidosis: the effect of a structured patient preparation protocol. J Nucl Cardiol. 2019;28(2):661–71.

    Article  PubMed  Google Scholar 

  70. Tang R, Wang JT-Y, Wang L, Le K, Huang Y, Hickey AJ, et al. Impact of patient preparation on the diagnostic performance of 18F-FDG PET in cardiac sarcoidosis: a systematic review and meta-analysis. Clin Nucl Med. 2016;41(7):e327–39.

    Article  PubMed  Google Scholar 

  71. Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol. 2014;63(4):329–36.

    Article  PubMed  Google Scholar 

  72. Ohira H, Tsujino I, Ishimaru S, Oyama N, Takei T, Tsukamoto E, et al. Myocardial imaging with 18 F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging. 2008;35(5):933–41.

    Article  PubMed  Google Scholar 

  73. Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg G, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med. 2012;53(2):241–8.

    Article  CAS  PubMed  Google Scholar 

  74. Kim S-J, Pak K, Kim K. Diagnostic performance of F−18 FDG PET for detection of cardiac sarcoidosis; a systematic review and meta-analysis. J Nucl Cardiol. 2019;27(6):2103–15.

    Article  PubMed  Google Scholar 

  75. Bravo PE, Raghu G, Rosenthal DG, Elman S, Petek BJ, Soine LA, et al. Risk assessment of patients with clinical manifestations of cardiac sarcoidosis with positron emission tomography and magnetic resonance imaging. Int J Cardiol. 2017;241:457–62.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Tuominen H, Haarala A, Tikkakoski A, Kähönen M, Nikus K, Sipilä K. FDG-PET in possible cardiac sarcoidosis: right ventricular uptake and high total cardiac metabolic activity predict cardiovascular events. J Nucl Cardiol. 2019;28(1):1–7.

    Google Scholar 

  77. Sperry BW, Tamarappoo BK, Oldan JD, Omair J, Culver DA, Richard B, et al. Prognostic impact of extent, severity, and heterogeneity of abnormalities on 18F-FDG PET scans for suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2018;11(2_Part_2):336–45.

    Article  PubMed  Google Scholar 

  78. Subramanian M, Swapna N, Ali AZ, Saggu DK, Yalagudri S, Kishore J, et al. Pre-treatment myocardial 18FDG uptake predicts response to immunosuppression in patients with cardiac sarcoidosis. JACC Cardiovasc Imaging. 2021;14(10):2008–16.

    Article  PubMed  Google Scholar 

  79. Yamamoto A, Nagao M, Watanabe E, Imamura Y, Suzuki A, Fukushima K, et al. Prognosis and recurrence in cardiac sarcoidosis: serial assessment of BMIPP SPECT and FDG-PET. J Nucl Cardiol. 2021;28(3):919–29. https://doi.org/10.1007/s12350-021-02567-0.

    Article  PubMed  Google Scholar 

  80. Hamzeh NY, Wamboldt FS, Weinberger HD. Management of cardiac sarcoidosis in the United States: a Delphi study. Chest. 2012;141(1):154–62.

    Article  CAS  PubMed  Google Scholar 

  81. Alvi RM, Young BD, Shahab Z, Pan H, Winkler J, Herzog E, et al. Repeatability and optimization of FDG positron emission tomography for evaluation of cardiac sarcoidosis. JACC Cardiovasc Imaging. 2019;12(7 Part 1):1284–7.

    Article  PubMed  Google Scholar 

  82. Miller RJ, Cadet S, Pournazari P, Pope A, Kransdorf E, Hamilton MA, et al. Quantitative assessment of cardiac hypermetabolism and perfusion for diagnosis of cardiac sarcoidosis. J Nucl Cardiol. 2020;29(1):86–96.

    Article  PubMed  Google Scholar 

  83. Okumura W, Iwasaki T, Toyama T, Iso T, Arai M, Oriuchi N, et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med. 2004;45(12):1989–98.

    PubMed  Google Scholar 

  84. Tahara N, Tahara A, Nitta Y, Kodama N, Mizoguchi M, Kaida H, et al. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis. JACC Cardiovasc Imaging. 2010;3(12):1219–28.

    Article  PubMed  Google Scholar 

  85. Langah R, Spicer K, Gebregziabher M, Gordon L. Effectiveness of prolonged fasting 18f-FDG PET-CT in the detection of cardiac sarcoidosis. J Nucl Cardiol. 2009;16(5):801–10.

    Article  PubMed  Google Scholar 

  86. Mc Ardle BA, Birnie DH, Klein R, de Kemp RA, Leung E, Renaud J, et al. Is there an association between clinical presentation and the location and extent of myocardial involvement of cardiac sarcoidosis as assessed by 18F-fluorodoexyglucose positron emission tomography? Circ Cardiovasc Imaging. 2013;6(5):617–26.

    Article  PubMed  Google Scholar 

  87. Osborne MT, Hulten EA, Singh A, Waller AH, Bittencourt MS, Stewart GC, et al. Reduction in 18F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. J Nucl Cardiol. 2014;21(1):166–74.

    Article  PubMed  Google Scholar 

  88. Ahmadian A, Brogan A, Berman J, Sverdlov AL, Mercier G, Mazzini M, et al. Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis. J Nucl Cardiol. 2014;21(5):925–39.

    Article  PubMed  Google Scholar 

  89. Lee P-I, Cheng G, Alavi A. The role of serial FDG PET for assessing therapeutic response in patients with cardiac sarcoidosis. J Nucl Cardiol. 2017;24(1):19–28.

    Article  PubMed  Google Scholar 

  90. Muser D, Santangeli P, Castro SA, Liang JJ, Enriquez A, Werner TJ, et al. Prognostic role of serial quantitative evaluation of 18F-fluorodeoxyglucose uptake by PET/CT in patients with cardiac sarcoidosis presenting with ventricular tachycardia. Eur J Nucl Med Mol Imaging. 2018;45(8):1394–404.

    Article  CAS  PubMed  Google Scholar 

  91. Manabe O, Ohira H, Hirata K, Hayashi S, Naya M, Tsujino I, et al. Use of 18F-FDG PET/CT texture analysis to diagnose cardiac sarcoidosis. Eur J Nucl Med Mol Imaging. 2019;46(6):1240–7.

    Article  CAS  PubMed  Google Scholar 

  92. Schildt JV, Loimaala AJ, Hippeläinen ET, Ahonen AA. Heterogeneity of myocardial 2-[18F] fluoro-2-deoxy-D-glucose uptake is a typical feature in cardiac sarcoidosis: a study of 231 patients. Eur Heart J Cardiovasc Imaging. 2018;19(3):293–8.

    Article  PubMed  Google Scholar 

  93. Manabe O, Koyanagawa K, Hirata K, Oyama-Manabe N, Ohira H, Aikawa T, et al. Prognostic value of 18F-FDG PET using texture analysis in cardiac sarcoidosis. JACC Cardiovasc Imaging. 2020;13(4):1096–7.

    Article  PubMed  Google Scholar 

  94. Hanneman K, Kadoch M, Guo HH, Jamali M, Quon A, Iagaru A, et al. Initial experience with simultaneous 18F-FDG PET/MRI in the evaluation of cardiac sarcoidosis and myocarditis. Clin Nucl Med. 2017;42(7):e328–34.

    Article  PubMed  Google Scholar 

  95. Wisenberg G, Thiessen J, Pavlovsky W, Butler J, Wilk B, Prato F. Same day comparison of PET/CT and PET/MR in patients with cardiac sarcoidosis. J Nucl Cardiol. 2019;27(6):2118–29.

    Article  PubMed  PubMed Central  Google Scholar 

  96. Soussan M, Brillet P-Y, Nunes H, Pop G, Ouvrier M-J, Naggara N, et al. Clinical value of a high-fat and low-carbohydrate diet before FDG-PET/CT for evaluation of patients with suspected cardiac sarcoidosis. J Nucl Cardiol. 2013;20(1):120–7.

    Article  PubMed  Google Scholar 

  97. Ohira H, Birnie DH, Pena E, Bernick J, Mc Ardle B, Leung E, et al. Comparison of 18F-fluorodeoxyglucose positron emission tomography (FDG PET) and cardiac magnetic resonance (CMR) in corticosteroid-naive patients with conduction system disease due to cardiac sarcoidosis. Eur J Nucl Med Mol Imaging. 2016;43(2):259–69.

    Article  CAS  PubMed  Google Scholar 

  98. Coulden RA, Sonnex EP, Abele JT, Crean AM. Utility of FDG PET and cardiac MRI in diagnosis and monitoring of immunosuppressive treatment in cardiac sarcoidosis. Radiol Cardiothorac Imaging. 2020;2(4):e190140.

    Article  PubMed  PubMed Central  Google Scholar 

  99. Reiter T, Werner RA, Bauer WR, Lapa C. Detection of cardiac sarcoidosis by macrophage-directed somatostatin receptor 2-based positron emission tomography/computed tomography. Eur Heart J. 2015;36(35):2404.

    Article  PubMed  Google Scholar 

  100. Lapa C, Reiter T, Kircher M, Schirbel A, Werner RA, Pelzer T, et al. Somatostatin receptor based PET/CT in patients with the suspicion of cardiac sarcoidosis: an initial comparison to cardiac MRI. Oncotarget. 2016;7(47):77807.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Gormsen LC, Haraldsen A, Kramer S, Dias AH, Kim WY, Borghammer P. A dual tracer 68 Ga-DOTANOC PET/CT and 18F-FDG PET/CT pilot study for detection of cardiac sarcoidosis. EJNMMI Res. 2016;6(1):1–12.

    Article  CAS  Google Scholar 

  102. Pizarro C, Kluenker F, Dabir D, Thomas D, Gaertner FC, Essler M, et al. Cardiovascular magnetic resonance imaging and clinical performance of somatostatin receptor positron emission tomography in cardiac sarcoidosis. ESC heart fail. 2018;5(2):249–61.

    Article  PubMed  Google Scholar 

  103. Slart RH, Koopmans K-P, van Geel PP, Kramer H, Groen HJ, Gan CT-J, et al. Somatostatin receptor based hybrid imaging in sarcoidosis. European j hybrid imaging. 2017;1(1):1–5.

    Article  Google Scholar 

  104. Martineau P, Pelletier-Galarneau M, Juneau D, Leung E, Nery PB, de Kemp R, et al. Imaging cardiac sarcoidosis with FLT-PET compared with FDG/perfusion-PET: a prospective pilot study. JACC Cardiovasc Imaging. 2019;12(11 Part 1):2280–1.

    Article  PubMed  Google Scholar 

  105. Norikane T, Yamamoto Y, Maeda Y, Noma T, Dobashi H, Nishiyama Y. Comparative evaluation of 18F-FLT and 18F-FDG for detecting cardiac and extra-cardiac thoracic involvement in patients with newly diagnosed sarcoidosis. EJNMMI Res. 2017;7(1):1–7.

    Article  Google Scholar 

  106. Weinberg RL, Morgenstern R, DeLuca A, Chen J, Bokhari S. F-18 sodium fluoride PET/CT does not effectively image myocardial inflammation due to suspected cardiac sarcoidosis. J Nucl Cardiol. 2017;24(6):2015–8.

    Article  PubMed  Google Scholar 

  107. Manabe O, Hirata K, Shozo O, Shiga T, Uchiyama Y, Kobayashi K, et al. 18F-fluoromisonidazole (FMISO) PET may have the potential to detect cardiac sarcoidosis. J Nucl Cardiol. 2017;24(1):329–31.

    Article  PubMed  Google Scholar 

  108. Dumas O, Abramovitz L, Wiley AS, Cozier YC, Camargo CA Jr. Epidemiology of sarcoidosis in a prospective cohort study of US women. Ann Am Thorac Soc. 2016;13(1):67–71.

    Article  PubMed  PubMed Central  Google Scholar 

  109. Ungprasert P, Crowson CS, Matteson EL. Influence of gender on epidemiology and clinical manifestations of sarcoidosis: a population-based retrospective cohort study 1976–2013. Lung. 2017;195(1):87–91.

    Article  PubMed  Google Scholar 

  110. Beghè D, Dall’ Asta L, Garavelli C, Pastorelli AA, Muscarella M, Saccani G, et al. Sarcoidosis in an Italian province. Prevalence and environmental risk factors. PLoS One. 2017;12(5):e0176859.

    Article  PubMed  PubMed Central  Google Scholar 

  111. Coquart N, Cadelis G, Tressières B, Cordel N. Epidemiology of sarcoidosis in Afro-Caribbean people: a 7-year retrospective study in Guadeloupe. Int J Dermatol. 2015;54(2):188–92.

    Article  PubMed  Google Scholar 

  112. Duchemann B, Annesi-Maesano I, de Naurois CJ, Sanyal S, Brillet P-Y, Brauner M, et al. Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of greater Paris. Eur Respir J. 2017;50(2):1602419.

    Article  PubMed  Google Scholar 

  113. Wu C-H, Chung P-I, Wu C-Y, Chen Y-T, Chiu Y-W, Chang Y-T, et al. Comorbid autoimmune diseases in patients with sarcoidosis: a nationwide case–control study in Taiwan. J Dermatol. 2017;44(4):423–30.

    Article  PubMed  Google Scholar 

  114. Fidler LM, Balter M, Fisher JH, To T, Stanbrook MB, Gershon A. Epidemiology and health outcomes of sarcoidosis in a universal healthcare population: a cohort study. Eur Respir J. 2019;54(4):1900444. https://erj.ersjournals.com/content/54/4/1900444.

    Article  PubMed  Google Scholar 

  115. Martineau P, Pelletier-Galarneau M, Juneau D, Leung E, Birnie D, Beanlands RSB. Molecular imaging of cardiac sarcoidosis. Curr Cardiovasc Imaging Rep. 2018;11(3):6.

    Article  Google Scholar 

  116. Yamagishi H, Shirai N, Takagi M, Yoshiyama M, Akioka K, Takeuchi K, et al. Identification of cardiac sarcoidosis with 13N-NH3/18F-FDG PET. J Nucl Med. 2003;44(7):1030–6.

    PubMed  Google Scholar 

  117. Ishimaru S, Tsujino I, Takei T, Tsukamoto E, Sakaue S, Kamigaki M, et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J. 2005;26(15):1538–43.

    Article  PubMed  Google Scholar 

  118. Ambrosini V, Zompatori M, Fasano L, Nanni C, Nava S, Rubello D, et al. 18F-FDG PET/CT for the assessment of disease extension and activity in patients with sarcoidosis: results of a preliminary prospective study. Clin Nucl Med. 2013;38(4):e171.

    Article  PubMed  Google Scholar 

  119. Manabe O, Yoshinaga K, Ohira H, Sato T, Tsujino I, Yamada A, et al. Right ventricular 18F-FDG uptake is an important indicator for cardiac involvement in patients with suspected cardiac sarcoidosis. Ann Nucl Med. 2014;28(7):656–63.

    Article  CAS  PubMed  Google Scholar 

  120. Ito K, Okazaki O, Morooka M, Kubota K, Minamimoto R, Hiroe M. Visual findings of 18F-Fluorodeoxyglucose positron emission tomography/computed tomography in patients with cardiac sarcoidosis. Intern Med. 2014;53(18):2041–9.

    Article  PubMed  Google Scholar 

  121. Momose M, Fukushima K, Kondo C, Serizawa N, Suzuki A, Abe K, et al. Diagnosis and detection of myocardial injury in active cardiac sarcoidosis—significance of myocardial fatty acid metabolism and myocardial perfusion mismatch. Circ J. 2015;79(12):CJ-15.

    Article  Google Scholar 

  122. Yokoyama R, Miyagawa M, Okayama H, Inoue T, Miki H, Ogimoto A, et al. Quantitative analysis of myocardial 18F-fluorodeoxyglucose uptake by PET/CT for detection of cardiac sarcoidosis. Int J Cardiol. 2015;195:180–7.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. BC Cancer, Vancouver, BC, Canada

    Patrick Martineau

  2. Montreal Heart Institute, Montréal, QC, Canada

    Matthieu Pelletier Galarneau

  3. Arrhythmia Service, Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, ON, Canada

    David Birnie

Authors
  1. Patrick Martineau
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthieu Pelletier Galarneau
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David Birnie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrick Martineau .

Editor information

Editors and Affiliations

  1. Montreal Heart Institute, Montréal, QC, Canada

    Matthieu Pelletier-Galarneau

  2. BC Cancer Agency, Vancouver, BC, Canada

    Patrick Martineau

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Martineau, P., Galarneau, M.P., Birnie, D. (2022). Cardiac Sarcoidosis. In: Pelletier-Galarneau, M., Martineau, P. (eds) FDG-PET/CT and PET/MR in Cardiovascular Diseases. Springer, Cham. https://doi.org/10.1007/978-3-031-09807-9_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-09807-9_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-09806-2

  • Online ISBN: 978-3-031-09807-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation